SEC Filings
Anson Reports 6.6% Silo Pharma Stake Through Private Funds It Co-Advises
The investment adviser shares voting authority over 103,983 shares held by private funds.
SEC Filings
The investment adviser shares voting authority over 103,983 shares held by private funds.
SEC Filings
Co-advised private funds hold the position, and the reporting persons certified it was held without a purpose of influencing control.
SEC Filings
Six reporting persons share authority over the same fund-held shares and certified the position was not held to influence control.
SEC Filings
The ownership amendment kept its passive classification and dated the zero-share position to September 30.
SEC Filings
The passive position includes shares receivable through warrants and convertible bonds, with some warrants subject to a 9.99% ownership limit.
SEC Filings
Private funds co-advised by Anson certified a passive purpose, while some warrants cap ownership through exercise at 9.99%.
SEC Filings
The disclosed portfolio grew to $19 billion, with options valued using their underlying shares rather than their purchase cost.
SEC Filings
The two reporting entities listed the same 11,456,114 shares, with the lung-disease drug's regulatory decision scheduled for Sunday.
SEC Filings
Stock awards dominated the 2025 package, while departing directors will leave new members overseeing executive pay.
SEC Filings
The holding company and investment adviser Polar Capital LLP each reported the same 5,022,084-share position.
SEC Filings
The hedge fund added Martin Marietta and Vulcan shares as the value of its disclosed US stock portfolio fell.
SEC Filings
Monday's ownership amendment dates the funds' zero-share position to September 30, 2025.